Table 3.
Dose-volume comparison of standard and bulboclitoris-sparing IMRT approaches for the entire bulboclitoris and bulboclitoris-PTV
| Prescription Dose: 50 Gy (N = 10) | Prescription Dose: 54 Gy (N = 10) | |||||||
|---|---|---|---|---|---|---|---|---|
| Structure | Percent Volume, Median (IQR), % | Difference, Median (IQR), % | sig. | Median Volume (IQR), % | Difference, Median (IQR), % | sig. | ||
| Dose Level | S-IMRT | BCS-IMRT | S-IMRT | BCS-IMRT | ||||
| Bulboclitoris | ||||||||
| 20 Gy | 100 (100, 100) | 97.3 (90.4, 100) | −0.4 (-7.4, 0.0) | 0.004 | 100 (98.7, 100) | 94.9 (91.6, 100) | −2.0 (-6.0,–4.3) | 0.06 |
| 30 Gy | 97.8 (79.8, 100) | 73.0 (66.7, 83.9) | −14.8 (-24.1,–5.6) | <0.001 | 99.9 (86.1, 100) | 77.1 (68.2, 87.0) | −15.8 (-18.4,–3.0) | 0.02 |
| 40 Gy | 73.7 (67.9, 89.2) | 65.6 (59.2, 75.2) | −9.0 (-11.7,–8.5) | <0.001 | 88.2 (63.6, 94.8) | 70.6 (56.2, 82.4) | −8.4 (-17.2,–1.2) | 0.02 |
| 50 Gy | 52.2 (39.0, 64.7) | 46.9 (36.7, 60.1) | −4.2 (-8.6,–0.4) | 0.003 | 63.9 (45.1, 71.6) | 52.4 (43.5, 69.3) | −5.1 (-8.2,–0.3) | 0.02 |
| Bulboclitoris-PTV | ||||||||
| 20 Gy | 100 (99.9, 100) | 94.9 (73.9, 100) | −2.7 (-21.1, 0) | 0.003 | 100 (97.7, 100) | 89.7 (75.8, 100) | −7.2 (-23.4,–16.9) | 0.04 |
| 30 Gy | 96.3 (76.4, 100) | 50.9 (41.0, 60.9) | −35.6 (-47.8,–19.0) | <0.001 | 99.9 (82.8, 100) | 56.9 (44.2, 61.4) | −35.6 (-42.6,–21.3) | 0.01 |
| 40 Gy | 52.5 (45.6, 70.9) | 32.7 (25.9, 40.6) | −19.6 (-32.6,–10.1) | <0.001 | 64.2 (48.8, 82.7) | 33.6 (28.5, 50.2) | −21.4 (-33.7,–7.6) | 0.03 |
| 50 Gy | 4.7 (2.5, 15.7) | 3.4 (0.2, 8.7) | −2.8 (-8.8,–0.3) | 0.005 | 15.9 (97.4, 38.3) | 7.1 (5.0, 25.8) | −9.3 (-12.0,–1.2) | 0.02 |
BCS-IMRT, bulboclitoris sparing IMRT; Gy, gray; IQR, interquartile range; PTV, planning target volume; PTV, planning target volume; S-IMRT, standard IMRT; sig, significance.
wilcoxon signed-rank tests,two-sided p<0.05 is significant.